Deleted in malignant brain tumor 1 (DMBT1) expression pattern in normal cervix and at different stages of squamous intraepithelial lesions by Valero, Andrés et al.
Send Orders for Reprints to reprints@benthamscience.ae
The Open Biomarkers Journal, 2018, 8, 1-8 1
1875-3183/18 2018  Bentham Open
The Open Biomarkers Journal
Content list available at: www.benthamopen.com/TOBIOMJ/
DOI: 10.2174/1875318301808010001
RESEARCH ARTICLE
Deleted in Malignant Brain Tumor 1 (DMBT1) Expression Pattern in
Normal  Cervix  and  at  Different  Stages  of  Squamous  Intraepithelial
Lesions
Andrés  Valero1,  María  Lorena  Roldán2,  María  Fernanda  Ruiz3,  Juan  Manuel  Teijeiro1,4,  Susana
Beatriz Marquez3 and Patricia Estela Marini1,2,5,*
1Laboratorio de Medicina Reproductiva, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de
Rosario, Rosario, Argentina
2Instituto de Biología Molecular y Celular de Rosario (IBR-CONICET), Rosario, Argentina
3Servicio de Anatomía Patológica, Hospital Provincial del Centenario - Facultad de Ciencias Médicas, Universidad
Nacional de Rosario, Rosario, Argentina
4Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Rosario, Argentina
5Consejo de Investigaciones de la Universidad Nacional de Rosario (CIUNR), Rosario, Argentina
Received: May 02, 2017 Revised: August 29, 2017 Accepted: October 30, 2017
Abstract:
Background:
Cervical  cancer  is  one  of  the  most  frequently  occurring malignancies  in  women worldwide,  with  high mortality  rates.  Cervical
Squamous Cell Carcinoma (SCC) presents previous states of non-invasive precursor lesions, and early stage Low-Grade Squamous
Intraepithelial  Lesions  (LSIL)  regress  to  normal  or  Atypical  Squamous  Cells  of  Undetermined  Significance  (ASCUS)  in
approximately 50% of cases. Deleted in Malignant Brain Tumors 1 (DMBT1) is a tumour suppression glycoprotein, which absence is
considered a malignancy marker in many epithelial cancers.
Objective:
To analyse DMBT1’s presence and localization in SCC and precursor lesions.
Method:
Immunohistochemistry for DMBT1 was performed in cervix biopsies classified as normal, LSIL, HSIL and SCC.
Results:
DMBT1 was detected at the supranuclear and sometimes infranuclear regions of the endocervix monolayer epithelial cells in normal
and  HSIL biopsies.  In  LSIL  samples  the  detection  of  DMBT1 in  endocervix  was  variable  between  patients.  Also  variable  was
DMBT1 staining in cells of glandular epithelium. The glycoprotein was not detected in the stratified epithelium of the exocervix,
regardless of the lesion grade; nor in dysplastic cells.
Conclusion:
The absence of DMBT1 from endocervix only in some samples of LSIL is promising as a candidate for possible lesion regression
potential marker.
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1. INTRODUCTION
One of the most frequently occurring malignant neoplasms in women worldwide is cervical cancer. It is responsible
for high mortality rates and is the fourth most common carcinoma among women on developing countries.  Almost
100% of cervical cancers are related to human papillomavirus (HPV) infections [1]. Such HPV-associated malignancy
may be prevented by prophylactic HPV vaccines, which are widely commercially available. However, despite that 58
countries have introduced HPV vaccination in their national immunization programs, one third of girls aged 13-17 have
not been fully vaccinated. Also, vaccination programs began in 2003, generally cover only females aged 11 to 13 years
old, and the protection vaccines provide is less than 90% [2]. This means that, although to a much lesser extent, women
around the world will continue to develop cervical squamous cell carcinoma (SCC) due to HPV infection.
SCC has well-defined clinical stages, presenting previous states of non-invasive precursor lesions such as Squamous
Intraepithelial  Lesions  (SIL).  Morphology  remains  the  standard  for  diagnosis  and  characterization  of  the  different
cervical lesions [3] and the characteristics of each stage are classified in the thoroughly used Bethesda System Atlas [4].
The full spectrum of carcinogenic lesions that occur in a normal cervix includes Low-Grade SIL (LSIL), High-Grade
SIL  (HSIL)  and  carcinoma  in  situ,  whereas  tumour  progression  is  composed  of  locally  invasive  SCC  and  distant
metastatic lesions. LSIL may regress to normal or atypical squamous cells of undetermined significance (ASCUS) with
a frequency of as much of 50% [5]. Therefore, it is important to identify cases that could potentially develop to HSIL at
an early stage of the disease and distinguish them from those with regression potential. Precursor lesions persist longer
and progress more quickly in women with oncogenic HPV infections than in women with non-oncogenic infections or
without HPV [3]. However, markers other than the presence of certain HPV strains are needed for accurate prognosis of
cervical lesions.
Deleted in Malignant Brain Tumors 1 (DMBT1, formerly gp340) is differentially expressed between certain stages
of carcinogenesis in many cancer types including colorectal [6], gastric [7], prostate [8], brain [9], breast [10] and lung
[11].  This  glycoprotein  is  a  member  of  the  Scavenger  Receptor  Cysteine-Rich  (SRCR)  family  [12]  and  has  been
suggested to play important roles in the innate immune defence against pathogens [13, 14], epithelial homeostasis [15],
inflammation, and tumour suppression [16]. These functions and their possible mechanisms are under constant study.
DMBT1  has  been  identified  in  numerous  epithelia,  bound  to  membranes,  and  in  secretions  such  as  tears,  saliva,
bronchoalveolar fluid and pancreatic juice [13, 17]. In women’s genital tract it has been reported in the Fallopian tube,
with a suggested role on epithelial protection and homeostasis, possibly related to epithelium-gamete interaction [18]. It
has also been studied in cervix, where it is proposed to be an HIV-binding molecule that, on its membrane bound form,
facilitates transmission of the virus to CD4+ target cells; in contraposition, its soluble form in fluids would prevent the
virus access to the mucosa [19]. In this last work, DMBT1 was detected in cervix by immunohistochemistry in the
differentiated spinous layer in the stratified squamous epithelia of the exocervix, with variations between individual
samples, and as patches in columnar epithelial cells at the endocervix, ranging from undetectable to intense between
individuals [19], however the diverse localization of the glycoprotein was not further analysed.
The presence of DMBT1 in the cervix epithelium, together with the reported variations on its expression during the
development of diverse epithelial cancers lead to the hypothesis that DMBT1’s expression or localization might vary
upon early carcinogenic lesions allowing to distinguish disease progression. To begin testing this hypothesis, in this
work we analyse by immunohistochemistry the expression of DMBT1 in cervix biopsies from normal tissue, LSIL,
HSIL and SCC.
2. MATERIALS AND METHODS
2.1. Study Design
A  retrospective  study  was  performed  on  24  cases  of  cervical  biopsies  and  conisations  performed  by  Loop
Electrosurgical  Excision  Procedure  (LEEP),  which  were  obtained  from  the  archives  of  Servicio  de  Anatomía
Patológica,  Hospital  Provincial  del  Centenario,  Facultad  de  Ciencias  Médicas,  Universidad  Nacional  de  Rosario
(Argentina).  The  specimens  were  examined  again  to  corroborate  diagnoses  under  the  morphological  classification
described in the Bethesda System Atlas [4]. The following diagnoses were represented: LSIL (5 cases), HSIL (7 cases),
SCC (5 cases) and normal (7 cases). Patient’s age ranged from 21 to 64 years, with a mean and standard deviation for
each group of 28 ± 7, 37 ± 5, 52 ± 7 and 48 ± 4 years old, respectively. Bioethics analysis of the project was precluded
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by Comisión de Bioética, Facultad de Ciencias Bioquímicas y Farmacéuticas, UNR, as samples came from archives.
Nevertheless, care was taken to maintain patient’s data anonymous. Data of HPV detection by PCR at the moment of
treatment were extracted from the clinical history of each patient.
2.2. Immunohistochemistry Staining
Histological sections 5 µm thick were generated and subsequently applied to silanized slides. Antigen retrieval was
performed  by  microwaving  slides  for  20  min  in  10  mM  trisodium  citrate  (pH  6).  Endogenous  peroxidases  were
inactivated by incubating slides for 30 min at 4ºC in 0.3% H2O2 in methanol, followed by three 5-min washes in Tris-
buffered saline (TBS, 50 mM Tris-Cl, pH 7.5, 150 mM NaCl). Sections were blocked with 5% skimmed milk, 0.2%
Triton X-100 in  TBS for  60 min and then treated with  anti-CUB antibodies  (diluted 1:25)  overnight  at  4ºC.  These
polyclonal antibodies have been validated for human DMBT1 detection by immunohistochemistry, western blot and
immunoprecipitation assays in previous studies [18, 20]. Secondary antibodies, anti-rabbit IgG-horseradish peroxidase
(diluted 1:100), were used in 2 h incubations. Horseradish peroxidase activity was visualized by development with 3,3′-
diaminobenzidine  tetrahydrochloride  and  the  reaction  was  stopped  by  washing  with  water.  Counterstaining  was
performed by Haematoxylin staining. Finally, the slides were mounted and analysed under Olympus BX40F4 (Japan)
microscope. Images were obtained with an Olympus Camedia C60 Zoom camera adapted for microscopy. All phases of
the  immunohistochemical  procedure  included  samples  for  positive  and  negative  controls.  The  positive  control  was
porcine oviduct [20] and for the negative control, preimmune serum was used.
3. RESULTS
3.1. DMBT1 Localization by Immunohistochemistry in Normal Cervix
Biopsy  specimens  from  normal  tissue  showed  characteristic  features  for  every  examined  region:  endocervix,
exocervix  and  transition  zone.  DMBT1  signal  was  detected  at  the  columnar  epithelial  cells  that  compose  the
 endocervix,  at   the supranuclear   cytoplasm  (Fig.  1A)  or  at   the infranuclear   cytoplasm  (Fig.  1B)   in all  of   the
samples  except for  one, that didn`t  present endocervical  epithelium  (Table 1). DMBT1  was also  frequently  present
 in the  epithelial  cells that  surround  the glands,  at the  supranuclear  region as well  as at  the infranuclear  cytoplasm
(Figs. 1A, C). Signal was undetectable at the stratified squamous epithelium of the exocervix and of the transition zone
(Figs. 1D, E). Interestingly, DMBT1 was undetectable in metaplastic cells that invade the DMBT1 positive monolayer
epithelia of endocervix and glands (Fig. 1C).
Table 1. DMBT1 detection in endocervix.
lesion DMBT1
normal + 6/7, ni 1/7
LSIL + 3/5, - 2/5
HSIL + 3/7, ni 4/7
+: signal for DMBT1 detected
-: undetectable staining for DMBT1
ni: endocervix region not identified in the biopsy
Table 1 summarizes the variability of DMBT1 detection between patients. As shown, at the endocervical epithelium
DMBT1’s presence was detected whenever the tissue was conserved in the specimens of patients classified as normal.
HPV detection by PCR was negative for all the patients (Table 2).


























+: signal for DMBT1 detected; positive HPV detection by PCR in serum
-: undetectable staining for DMBT1; negative HPV detection by PCR in serum
ni: endocervix region not identified in the biopsy
Fig. (1). Representative microphotographs of immunohistochemical analysis for DMBT1 of normal cervix biopsies. A, B-
endocervix, arrows show specific staining at supranuclear (A) and infranuclear (B) regions. C- gland positive for DMBT1, arrows
show metaplastic cells negative for DMBT1 staining. D- exocervix, E- transition zone, both negative for DMBT1. F- control using
pre-immune serum. Bars indicate 50 μm (A, B) and 100 μm (C, D, E, F).
3.2. DMBT1 Localization by Immunohistochemistry in LSIL
In cervix biopsies classified as LSIL according to the Bethesda System Atlas, DMBT1’s signal was detected in
some samples that conserved endocervix and glands with normal cell morphology and distribution. In these samples,
DMBT1 was present at the supranuclear or infranuclear cytoplasm of the epithelial monolayer cells (Fig. 2C) and at the
cells that form some of the glands. However, DMBT1 could not be detected in all of the samples that exhibited normal
endocervical tissue (Table 1). As in normal tissue, DMBT1 was undetectable at the stratified epithelia of the exocervix
and transition zones (Figs. 2A, B).
(Table ) contd.....
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Fig. (2). Representative microphotographs of immunohistochemical analysis for DMBT1 of cervix biopsies with different
grades  of  lesion.  A-  exocervix  from  LSIL  biopsy,  B-  2x  amplification  of  A  showing  koilocytes.  C-  endocervix  of  columnar
epithelium  with  infranuclear  DMBT1  specific  staining  (arrows)  in  LSIL  specimen.  D-  HSIL  specimen  showing  recognizable
detached endocervix monolayer epithelium, positive for DMBT1 staining (arrows). E- exocervix and glands in HSIL specimen. F-
SCC with non-recognisable cervix regions. Bars indicate 100 μm (A, E, F), 50 μm (B, D) and 25 μm (C).
Although the number of examined samples does not allow further analysis, it is to note that the detection of DMBT1
in  cervix  specimens  did  not  relate  to  the  use  of  hormonal  contraceptive  methods.  Also,  HPV  detection  by  DNA
amplification, as registered in the clinical histories, was positive in 4/5 LSIL patients and did not show correlation to
DMBT1 detection (Table 2).
3.3. DMBT1 Localization by Immunohistochemistry in HSIL
When cervix biopsies classified as HSIL were analysed by immunohistochemistry for DMBT1, the endocervix was
absent  or  not  recognizable  in  most  of  the  samples,  but  it  was  positive  for  DMBT1  in  the  three  samples  in  which
characteristic monolayer epithelia of columnar cells was recognized (Fig. 2D, Table 1). These epithelia were frequently
found as detached fragments, devoid of corion (Fig. 2D). Signal was also detected in cells of glandular epithelium in
most of the tested samples. In exocervix tissue that conserved integrity, DMBT1 signal was not detected (Fig. 2E). In
one of the biopsies the different regions of the cervix could not be recognized. This particular sample showed patches of
positive signal (not shown). DMBT1 was not detected in cells showing cytological atypia.
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3.4. DMBT1 Detection by Immunohistochemistry in SCC
Cervix  biopsies  classified  as  SCC by the  Servicio  de  Anatomía  Patológica,  Hospital  Provincial  del  Centenario,
showed tissue that had lost its integrity preventing the assignment of the typical cervix regions: endocervix, transition
zone and exocervix. None of the analysed samples exhibited detectable signal for DMBT1 (Fig. 2F), although minor
unspecific staining of some cell debris was noted in some specimens.
4. DISCUSSION
The lack or diminution of DMBT1 is considered a malignancy biomarker in many epithelial cancers, and the high
regression rate of LSIL promotes the search of biomarkers that allow distinguishing between those lesions that will
progress to HSIL and eventually cancer from those that will proceed to regression. However, to our best knowledge, the
expression of DMBT1 has not still been analysed in SCC’s preceding lesions.
In order to begin studying the role of DMBT1 in cervix cancer establishment, and to challenge the hypothesis that a
decrease in this  glycoprotein might  be a marker of  malignancy in the lesions that  precede cancer development,  we
analysed  the  presence  and  localization  of  the  glycoprotein  in  cervix  biopsies  with  different  grades  of  lesion  by
immunohistochemistry. This technique has become an integral part in diagnostic pathology, as an adjunct method that
helps resolve diagnostic dilemmas and can be used as predictive or as prognostic [21].
In cervix, DMBT1 has been assigned an undesirable role in facilitating human HIV binding and transmission to host
cells [19, 22]. It is interesting to note that no difference was observed in DMBT1 localization in HIV positive patients
(not  shown).  Most  cervical  cancers  can  be  associated  to  infection  by  HPV,  which  causes  cervical  cancer  and  its
precursor lesions, specifically at the squamocolumnar junction [23, 24], near the transformation zone. Specific cytokine
7 staining patterns have been proposed to distinguish a subpopulation of cells at the squamocolumnar junction which
presence indicates potentially aggressive SILs [25]. Although HIV and HPV belong to very different viral types with
different mechanisms of infection (lentivirus and Papillomaviridae, respectively), a facilitating effect for DMBT1 in
HPV infection, similar to that described for HIV, can be thought. Also, in a transgenic mouse model, the expression of
the HPV’s E7 oncoprotein in cervix has been shown to produce a decrease of DMBT1’s RNA, detected in microarray
experiments [26]. This evidence would support a protective role for DMBT1 in cervix, preventing malignancy advance,
and the possible use of its diminution as reflection of malignancy progression. However, in this work, no particularity
could be assigned to DMBT1’s expression in the transition zone in neither of the analysed stages of lesion.  In this
region, mature squamous cells (negative for DMBT1 staining, Figs. 1 and 2 move underneath the endocervical cells,
which are positive for DMBT1 in all samples tested, except for some LSIL (Table 1 and 2). Also, no correlation was
found between HPV infection and DMBT1 expression in human cervix (Table 2).
DMBT1’s detection by immunohistochemistry (Table 1) shows that the glycoprotein is detected in endocervix and
some gland cells classified as normal by their morphological characteristics in all the normal and HSIL biopsies in
which the region could be recognized. In LSIL instead, endocervix devoid of the glycoprotein was observed in some
patient’s  samples.  In  exocervix,  DMBT1  was  not  detected  in  any  of  the  analysed  specimens  disrespectful  of  the
presence or grade of lesion (n=17). These results are different from the presented by Patyka et al. [19]; who studied
biopsies from patients without lesions, finding variations between normal patients, and DMBT1 distributed as patches
of granules in few and disperse columnar epithelial cells including the mucosal surface at the endocervix, and as diffuse
granular staining throughout the stratified epithelium of exocervix. The difference might respond to the use of different
antibodies.  While  the  previous  work  utilized  monoclonal  antibodies,  in  this  study  we  use  polyclonal  antibodies
developed in rabbit and validated by western blot, immunohistochemistry and immunoprecipitation [18, 20], which
probably recognize several exposed epitopes of the glycoprotein .
It is to note that DMBT1 was undetectable in cells showing mild or severe alterations in every sample tested from
all the analysed stages (n=17). Interestingly, only at the early LSIL stage, when a potent biomarker of malignancy is
needed, the expression of DMBT1 in endocervix was variable between samples. Although progression of the illness
could not be registered, these results are encouraging as to the possible utility of DMBT1 as a progression marker. Lack
of DMBT1 was noted in the biopsies from SCC, but at this stage the integrity of the tissue is completely lost and the
histological characteristics are evident.
DMBT1’s expression is specifically induced by oestrogen in glandular and luminal epithelia of rat endometrium
[27],  by progesterone at  normal  secretory levels  in  Rhesus monkey  endometrium [28],  and is  greater  in  ewe cervix
secretions in luteal phase than in oestrus [29]. Thus, the possible influence of hormonal contraconception treatment or
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the  moment  of  the  female  cycle  in  the  expression  of  DMBT1  in  biopsies  of  human  cervix  was  considered.  No
relationship  was  detected,  however  a  greater  amount  of  samples  should  be  analysed  to  discard  ovarian  hormonal
influences on the cervical expression of DMBT1 in women.
CONCLUSION
DMBT1 was not detected in altered cells nor in exocervix stratified epithelia, but was present in normal endocervix
epithelial cells. Lack of detection of DMBT1 in the endocervical epithelium was exclusive to LSIL grade lesions in
precancerous biopsies.
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